Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
December 12, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…
Teva Releases Q4 2025 Aide Memoire
December 12, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citis 2025 Global Healthcare Conference in December
November 21, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November
October 31, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…
FDA Approves Expanded Indication for UZEDY (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy…
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
September 25, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL…
Patients Taking AUSTEDO XR (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94%…
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
